Leo Pharma presents positive data in hand eczema phase III trial
The Danish dermatology company’s hand eczema candidate, delgocitinib, met all endpoints in late-stage testing.
by ulrich quistgaard, translated by daniel pedersen
Leo Pharma’s chronic hand eczema asset, delgocitinib, has made it across the finish line of a phase III trial called Delta 1.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma reaches endpoints in phase III hand eczema trial
For subscribers
